Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29944605 | 0.76 | CNR2 (0.71) | MAPTLMNATP53POLBNPSR1 | |
| SCHEMBL3401540 | 0.74 | MEN1 (0.63) | MAPTLMNATP53MEN1KMT2A | |
| SCHEMBL16557481 | 0.74 | MEN1 (0.76) | MAPTLMNAMEN1KMT2AHTT | |
| SCHEMBL16557575 | 0.70 | POLB (0.81) | TP53MEN1KMT2AHTTPOLB | |
| SCHEMBL14224535 | 0.70 | LMNA (0.52) | LMNATP53MEN1KMT2ANPSR1 | |
| SCHEMBL16557561 | 0.69 | HPGD (0.65) | MAPTLMNATP53MEN1KMT2A | |
| SCHEMBL23135793 | 0.68 | TDP1 (0.60) | MAPTLMNAMEN1KMT2AHTT | |
| SCHEMBL806586 | 0.68 | POLB (0.77) | MAPTMEN1KMT2AHTTPOLB | |
| SCHEMBL806585 | 0.67 | POLB (0.69) | MAPTLMNAMEN1KMT2AHTT | |
| SCHEMBL31222507 | 0.67 | MAPT (0.66) | MAPTALOX15LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | BIOMARIN PHARMACEUTICAL INC. | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | ENGASE, GALNT1, GALNT13 | MAPT 2982/4885ALOX15 3238/4885LMNA 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.